ADVERUM BIOTECHNOLOGIES - Revizia istoricului

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-11-23T21:02:28Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 24 noiembrie 2024 00:02
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Adverum Biotechnologies, Inc. (https://adverum.com/) is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a [[one]]-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.		Adverum Biotechnologies, Inc. (https://adverum.com/) is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration ([[AMD]]) and diabetic macular edema (DME). ADVM-022, is given as a [[one]]-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the [[INFINITY]] trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.

	==Grafic actiuni companie==		==Grafic actiuni companie==

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-09-29T00:05:27Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 29 septembrie 2024 03:05
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Adverum Biotechnologies, Inc. (https://adverum.com/) is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.		Adverum Biotechnologies, Inc. (https://adverum.com/) is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a [[one]]-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.

	==Grafic actiuni companie==		==Grafic actiuni companie==

Admin: Pagină nouă: Pagina dedicata companiei ADVERUM BIOTECHNOLOGIES listata cu simbolul US.ADVM ==Descriere companie== Adverum Biotechnologies, Inc. (https://adverum.com/) is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-ti...

2024-09-18T13:35:28Z

Pagină nouă: Pagina dedicata companiei ADVERUM BIOTECHNOLOGIES listata cu simbolul US.ADVM ==Descriere companie== Adverum Biotechnologies, Inc. (https://adverum.com/) is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-ti...

Pagină nouă

Pagina dedicata companiei ADVERUM BIOTECHNOLOGIES listata cu simbolul US.ADVM

==Descriere companie==
Adverum Biotechnologies, Inc. (https://adverum.com/) is a clinical-stage gene therapy company targeting ocular and rare diseases. It develops gene therapy product candidates. Its ADVM-022, is a clinical-stage gene therapy product candidate developed for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME). ADVM-022, is given as a one-time in-office intravitreal (IVT) injection and is designed to reduce the burden of anti-vascular endothelial growth factor (anti-VEGF) injections, optimize patient compliance and improve vision outcomes for patients with wet AMD or DME. It is conducting the OPTIC trial, designed as a multi-center, open-label, Phase I, dose-ranging safety trial of ADVM-022 in patients with wet AMD, who have demonstrated responsiveness to anti-VEGF treatment. It is also conducting the INFINITY trial, a multi-center, Phase II, randomized, double-masked, active comparator-controlled study evaluating a single IVT injection of ADVM-022 in patients with DME.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.ADVM" />

==Ultimele stiri despre ADVERUM BIOTECHNOLOGIES (US.ADVM)==
<dynamicpagelist>
category=US.ADVM
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.ADVM]][[Categorie:Stiri despre companii]]